Role of Eicosanoids in Prostate Cancer Progression

Metabolism of arachidonic acid through cyclooxygenase, lipoxygenase, or P450 epoxygenase pathways leads to the formation of various bioactive eicosanoids. In this review, we discuss alterations in expression pattern of eicosanoid-generating enzymes found during prostate tumor progression and expound upon their involvement in tumor cell proliferation, apoptosis, motility, and tumor angiogenesis. The expression of cyclooxygenase-2, 12-lipoxygenase, and 15-lipoxygenase-l are up-regulated during prostate cancer progression. It has been demonstrated that inhibitors of cyclooxygenase-2, 5-lipoxygenase and 12-lipoxygenase cause tumor cell apoptosis, reduce tumor cell motility and invasiveness, or decrease tumor angiogenesis and growth. The eicosanoid product of 12-lipoxygenase, 12(S)-hydroeicosatetraenoic acid, is found to activate Erkl/2 kinases in LNCaP cells and PKCα in rat prostate AT2.1 tumor cells. Overexpression of 12-lipoxygenase and 15-lipoxygenase-l in prostate cancer cells stimulate prostate tumor angiogenesis and growth, suggesting a facilitative role for 12-lipoxygenase and 15-lipoxygenase-l in prostate tumor progression. The expression of 15-lipoxygenase-2 is found frequently to be lost during the initiation and progression of prostate tumors. 15(S)-hydroxyeicosatetraenoic acid, the product of 15-lipoxygenase-2, inhibits proliferation and causes apoptosis in human prostate cancer cells, suggesting an inhibitory role for 15-lipoxygenase-2 in prostate tumor progression. The regulation of prostate cancer progression by eicosanoids, in either positive or negative ways, provides an exciting possibility for management of this disease.

[1]  M. Vos,et al.  5‐lipoxygenase inhibitors reduce PC‐3 cell proliferation and initiate nonnecrotic cell death , 1998, The Prostate.

[2]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[3]  K. Honn,et al.  Eicosanoid Activation of Extracellular Signal-regulated Kinase1/2 in Human Epidermoid Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[4]  D. Grignon,et al.  Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. , 1998, Cancer research.

[5]  A. Levine,et al.  Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line , 2004, Clinical & Experimental Metastasis.

[6]  M. Kondo,et al.  15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats , 2000 .

[7]  J. Tímár,et al.  Immunomorphological characterization and effects of 12-(S)-HETE on a dynamic intracellular pool of the alpha IIb beta 3-integrin in melanoma cells. , 1995, Journal of cell science.

[8]  W. Hagmann,et al.  Differential secretion of cathepsins B and L from normal and tumor human lung cells stimulated by 12(S)-hydroxy-eicosatetraenoic acid. , 1996, Experimental cell research.

[9]  R. Jackson,et al.  Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case–control study , 1999, British Journal of Cancer.

[10]  R. Dahiya,et al.  Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. , 1997, British Journal of Cancer.

[11]  A. Brash,et al.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.

[12]  U. Kelavkar,et al.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. DuBois,et al.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Honn,et al.  12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes. , 1995, Prostaglandins.

[16]  J. Tímár,et al.  PKC mediates 12(S)-HETE-induced cytoskeletal rearrangement in B16a melanoma cells. , 1993, Cell motility and the cytoskeleton.

[17]  D. Nie,et al.  Eicosanoid 12(S)-HETE activates phosphatidylinositol 3-kinase. , 2000, Biochemical and biophysical research communications.

[18]  J. Tímár,et al.  Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants. , 1994, Cancer research.

[19]  A. Levine,et al.  Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. , 2000, The Journal of urology.

[20]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[21]  D. Bostwick,et al.  Lipoxygenase‐5 is overexpressed in prostate adenocarcinoma , 2001, Cancer.

[22]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[23]  Y. Hannun,et al.  12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[25]  C. Coffey,et al.  Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. , 2000, Human pathology.

[26]  P. Vickers,et al.  5-Lipoxygenase-activating protein (FLAP). , 1995, Journal of lipid mediators and cell signalling.

[27]  D. Grignon,et al.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. , 1995, Urology.

[28]  C. Myers,et al.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Marnett,et al.  Biosynthesis of 12(S)-hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[30]  K. Honn,et al.  Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Andrew C. Li,et al.  Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. , 2000, The Journal of clinical investigation.

[32]  U. Kelavkar,et al.  Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. , 2000, Carcinogenesis.

[33]  B. Liu,et al.  Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. , 1994, Cancer research.

[34]  U. Kelavkar,et al.  Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. , 2001, Carcinogenesis.

[35]  S. Biswal,et al.  The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. , 1999, The Biochemical journal.

[36]  P. Unger,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. , 2000, Urology.

[37]  G. Piazza,et al.  Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. , 1999, Biochemical pharmacology.

[38]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[39]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[40]  S. Biswal,et al.  Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886 , 2001 .

[41]  A. Levine,et al.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. , 1998, Cancer research.

[42]  D. Rose,et al.  Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. , 1998, Cancer letters.

[43]  J. Tímár,et al.  12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis , 1994, Cancer and Metastasis Reviews.

[44]  A. Brash,et al.  Discovery of a second 15S-lipoxygenase in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Nie,et al.  Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. , 2000, Blood.

[46]  K. Honn,et al.  Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)‐HETE‐induced endothelial cell retraction , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  D. Bostwick,et al.  Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.

[48]  J. Kehrer,et al.  A Relationship between 5-Lipoxygenase-activating Protein and bcl-xL Expression in Murine Pro-B Lymphocytic FL5.12 Cells* , 1998, The Journal of Biological Chemistry.

[49]  F. Sarkar,et al.  Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. , 1997, Biochemical and biophysical research communications.

[50]  M. Kondo,et al.  15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. , 2000, The Journal of clinical investigation.

[51]  Y. Hannun,et al.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. , 1994, Journal of the National Cancer Institute.

[52]  T. Hla,et al.  Expression of cyclooxygenase‐2 in prostate carcinoma , 2000, Cancer.

[53]  C. Pan,et al.  Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. , 2001, Anticancer research.

[54]  A. Weeraratna,et al.  Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. , 2000, Cancer research.

[55]  M. Nevalainen,et al.  Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer , 2001, Urological Research.